MIM
ATOS icon

MetLife Investment Management’s Atossa Therapeutics ATOS Stock Holding History

MetLife Investment Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,599
Closed -$36.4K – 2815
2024
Q3 		$36.4K Sell
1,599
-628
-28% -$12.7K ﹤0.01% 2785
2024
Q2 		$39.8K Buy
+2,227
New +$49.3K ﹤0.01% 2792
2021
Q4 		– Sell
-1,328
Closed -$64.9K – 2501
2021
Q3 		$64.9K Sell
1,328
-1,605
-55% -$93.4K ﹤0.01% 2516
2021
Q2 		$278K Buy
+2,933
New +$155K ﹤0.01% 1937

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MetLife Investment Management's ATOS Position: Q4 2024 in Review

MetLife Investment Management sold out of Atossa Therapeutics (ATOS) in Q4 2024, closing a stake of 1,599 shares — an estimated $36.4K sold.

MetLife Investment Management first reported a position in ATOS in Q2 2021 and held it in 4 quarters. The position peaked at $278K in Q2 2021. 86 funds tracked by Wall St. Rank hold ATOS as of Q4 2024.

  • MetLife Investment Management reported no remaining Atossa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 1,599 Atossa Therapeutics shares in Q4 2024, an estimated $36.4K.
  • MetLife Investment Management first reported a position in Atossa Therapeutics in Q2 2021 and held it in 4 quarters.
  • MetLife Investment Management's Atossa Therapeutics position peaked at $278K in Q2 2021.
  • 86 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.